E-LIB Suche - Ergebnisse für: Hillmen, P.

1

P663: HEALTH-RELATED QUALITY OF LIFE OUTCOMES ASSOCIATED WI..:

Hillmen, P. ; Brown, J. ; Lamanna, N....
HemaSphere. 6 (2022) - p. 561-562 , 2022

Link: https://doi.org/10.1097/..

2

S146: VENETOCLAX IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKE..:

Stilgenbauer, S. ; Tausch, E. ; Roberts, A. W....
HemaSphere. 6 (2022) - p. 47-48 , 2022

Link: https://doi.org/10.1097/..

3

P673: DEPLETION AND RECOVERY OF NORMAL B-CELLS DURING AND A..:

Rawstron, A. ; Webster, N. ; Pitchford, A....
HemaSphere. 6 (2022) - p. 571-572 , 2022

Link: https://doi.org/10.1097/..

4

P662: PATIENT-REPORTED OUTCOMES FROM A PHASE 3 RANDOMIZED S..:

Ghia, P. ; Barnes, G. ; Yang, K....
HemaSphere. 6 (2022) - p. 560-561 , 2022

Link: https://doi.org/10.1097/..

5

S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS ..:

Hillmen, P. ; Pitchford, A. ; Bloor, A....
HemaSphere. 6 (2022) - p. 46-47 , 2022

Link: https://doi.org/10.1097/..

6

P791: COMMON VARIANTS IN COMPLEMENT PROTEINS, C3 AND CR1, E..:

Baral, A. J. ; Mckinley, C. ; Fellows, R....
HemaSphere. 6 (2022) - p. 686-687 , 2022

Link: https://doi.org/10.1097/..

7

FIRST‐LINE TREATMENT WITH IBRUTINIB FOR PATIENTS WITH CHRON..:

Coutre, S. E. ; Barr, P. M. ; Owen, C....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

8

UNFAVORABLE GENETICS IMPACT MRD RESPONSE TO VENETOCLAX+RITU..:

Wu, J. Q. ; Seymour, J. F. ; Eichhorst, B....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

9

FIRST RESULTS OF A HEAD‐TO‐HEAD TRIAL OF ACALABRUTINIB VERS..:

Hillmen, P. ; Byrd, J. C. ; Ghia, P....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

10

Antibody responses after first and second Covid-19 vaccinat..:

Parry, H. ; McIlroy, G. ; Bruton, R....
Blood Cancer Journal. 11 (2021) 7 - p. , 2021

Link: https://doi.org/10.1038/..

11

RESULTS OF THE PEGASUS PHASE 3 RANDOMIZED TRIAL DEMONSTRATI..:

Weitz, H. ; Hillmen, P. ; Szer, J....
Hematology, Transfusion and Cell Therapy. 42 (2020) - p. 12-13 , 2020

Link: https://doi.org/10.1016/..

12

FIVE‐YEAR FOLLOW‐UP OF FIRST‐LINE IBRUTINIB FOR TREATMENT O..:

Tedeschi, A. ; Burger, J. ; Barr, P.M....
Hematological Oncology. 37 (2019) S2 - p. 103-104 , 2019

Link: https://doi.org/10.1002/..

13

BRIEF CO‐ADMINISTRATION OF IDELALISIB MAY IMPROVE THE LONG‐..:

Pettitt, A. ; Kalakonda, N. ; Cicconi, S....
Hematological Oncology. 37 (2019) S2 - p. 217-218 , 2019

Link: https://doi.org/10.1002/..

14

IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/..:

Wu, J. ; Bolen, C. ; Seymour, J.F....
Hematological Oncology. 37 (2019) S2 - p. 106-108 , 2019

Link: https://doi.org/10.1002/..

15

AN IMPROVED BENEFIT‐RISK PROFILE OF DUVELISIB IN PATIENTS W..:

Flinn, I.W. ; Davids, M.S. ; Hillmen, P....
Hematological Oncology. 37 (2019) S2 - p. 213-214 , 2019

Link: https://doi.org/10.1002/..